Biocon Biologics

What Biocon Biologics does

Biocon Biologics is a fully integrated, pure-play biosimilars company headquartered in Bangalore, India, and now a wholly owned subsidiary of Biocon Limited following full integration completed in 2026. The company develops, manufactures, and commercializes high-quality, affordable biosimilars across three primary therapeutic verticals: diabetes care (insulin glargine, insulin aspart, semaglutide biosimilar Glupryze, and liraglutide generic gSaxenda), oncology (trastuzumab, bevacizumab, denosumab under brands Bosaya, Aukelso, Vevzuo, and Evfraxy, plus ustekinumab as Yesintek), and immunology (adalimumab as Hulio). It serves 6+ million patients annually across 100+ countries, with 10 biosimilars commercialized globally and 20 in its broader pipeline.

The company's core technology rests on a proprietary Pichia pastoris expression platform for recombinant proteins (pioneered commercially with human insulin in 2004), mammalian cell culture capabilities, and integrated fill-finish manufacturing across facilities in India and Malaysia (including Asia's largest insulin plant at RM1.63 billion in Johor). It holds multiple first-to-market regulatory milestones, including the first US FDA interchangeable biosimilar designations for bGlargine (2021), bAflibercept (2024), and bAspart (2025), and the first FDA approvals for biosimilar trastuzumab and pegfilgrastim.

Revenue is generated through a hybrid commercial model: direct enterprise field sales and specialty pharmacy distribution in advanced regulated markets (US, EU, Canada, Japan, Australia), combined with tender-based and distributor-led sales in emerging markets. The business is anchored by biosimilars (~60% of FY26 revenue), with secondary contributions from generics (~18-24%), CRDMO services through Syngene International, and insulin manufacturing partnerships (notably Civica for the US CalRx program at $11/vial). FY26 consolidated operating revenue was ₹16,927 crore, with biosimilars growing 16% year-over-year and EBITDA up 40% on a like-to-like basis.

Name

Biocon Biologics

Legal name

Biocon Biologics Limited

Website

https://bioconbiologics.com

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Biocon Biologics is a Bangalore-based, fully integrated biosimilars company developing and commercializing affordable biosimilar therapies for diabetes, oncology, and immunology, serving 6+ million patients annually across 100+ countries with first-to-market FDA interchangeable designations.

Ownership category

akta.pro rank

Product category

Biosimilar Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration) (HLAAAHAK)

akta.pro secondary industries

Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution) (HLAAAHAL), Oncology Biosimilars (HLAAAHAG), Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance) (HLAAAHAJ), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Biologics & Biosimilars Distributors (HLAIAJAH)

Keywords

• Biosimilar pharmaceuticals
• Monoclonal antibodies
• Insulin manufacturing
• Oncology biosimilars
• Biologics drug development

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biosimilars: Sale of biosimilar products globally through direct commercialization in advanced markets and partnerships in emerging markets. Includes insulins, monoclonal antibodies, and oncology biosimilars. Contributed approximately 60% of total revenue in FY26.
2. Generics: Sale of generic pharmaceutical products including complex generics, oral solid dose, and injectable formulations. Contributed approximately 18-24% of revenue with Q4FY26 revenue of ₹847 crore.
3. CRDMO Services: Contract research and manufacturing services through Syngene International, providing integrated discovery, development, and manufacturing services to global pharma clients.
4. Insulin Manufacturing & Supply: Manufacturing and supply of insulin products to partners like Civica for US market commercialization under CalRx program and other global insulin supply agreements.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Biocon Biologics is a fully integrated biosimilars company that develops, manufactures, and commercializes affordable biosimilar versions of biologic drugs including insulins, monoclonal antibodies (oncology and immunology), and conjugated recombinant proteins. It sells these products directly in advanced regulated markets and through partnerships in emerging markets, supplying healthcare systems across 100+ countries.

Product overview

Biocon Biologics is a fully integrated biosimilars company offering a portfolio of 20 biosimilars with 10 commercialized in global markets across the US, EU, Australia, Canada, Japan, and over 100 countries. The portfolio spans insulins (Insulin Glargine, Insulin Aspart), monoclonal antibodies (Adalimumab/Hulio, Ustekinumab/Yesintek, Denosumab/Bosaya, Aukelso, Vevzuo, Evfraxy), and conjugated recombinant proteins. Key products include generic Micafungin for antifungal treatment and gSaxenda (Liraglutide generic) for obesity. The company operates across advanced markets (US, EU, Canada, Japan) and emerging markets, with manufacturing facilities in India and Malaysia.

Differentiator

Problem solved

Functional benefit

Brands

• Bosaya: Denosumab biosimilar for treating osteoporosis and bone complications from cancer, launched in the US in April 2026
• Aukelso
• Yesintek
• Hulio
• Vevzuo
• Evfraxy
• Glupryze
• gSaxenda

Products and services

• Bosaya (Denosumab Biosimilar) A denosumab biosimilar for treating osteoporosis and bone complications from cancer, with interchangeable designation from US FDA. Distributed through specialty pharmacies in the US.
• Aukelso (Denosumab Biosimilar) A denosumab biosimilar for treating osteoporosis and bone complications from cancer, with interchangeable designation from US FDA. Distributed through specialty pharmacies in the US.
• Yesintek / Yesintek I.V. (Ustekinumab Biosimilar) Biosimilar to Stelara approved by Health Canada for treating autoimmune conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Yesintek captured nearly 20% US market share for ustekinumab biosimilar.
• Hulio (Adalimumab Biosimilar) Adalimumab biosimilar for treating autoimmune conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Biocon acquired full global rights in December 2025.
• Insulin Glargine (Private Label) Long-acting insulin glargine manufactured by Biocon and distributed by Civica under private label in the US market, interchangeable with Lantus. Part of California CalRx program offering 40-70% discount to market prices.
• gSaxenda (Liraglutide Generic) Generic version of GLP-1 weight management drug Liraglutide (Saxenda), approved by USFDA for obesity treatment in the US market.
• Micafungin for Injection Antifungal injection approved by Health Canada for treating Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses, esophageal candidiasis, and prophylaxis of Candida infections in adults and children four months and older.
• Vevzuo (Denosumab Biosimilar) Denosumab biosimilar targeting skeletal-related events in cancer patients, launched in Europe from December 2025 following Amgen settlement.
• Evfraxy (Denosumab Biosimilar) Denosumab biosimilar for treating osteoporosis, launched in Europe from December 2025 following Amgen settlement.

Quantifiable outcome

• 6+ million patients benefit annually from biosimilar therapies
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• BahiaFarma and BionovisminorStrategic or Co-development Partner · 23 February 2026MoU signed at Ficci India-Brazil Business Forum for developing pertuzumab biosimilar for HER-2 metastatic breast cancer treatment in Brazil, in presence of Brazilian President Lula da Silva.
• Fujifilm Kyowa Kirin Biologics (FKB)coreStrategic or Co-development Partner · 23 December 2025Expanded deal to acquire full global rights for adalimumab biosimilar (Hulio), replacing previous partnership with complete control over manufacturing, commercialization, and future development. FKB continues supporting development with technology transfer.
• AmgencoreStrategic or Co-development Partner · 3 December 2025Settlement agreement to commercialize denosumab biosimilars (Vevzuo, Evfraxy) in Europe and international markets. Both biosimilars received European Commission approval in July 2025. Agreement builds on prior US settlement.
• CivicacoreChannel Partner/ Reseller/ Distributor · 16 October 2025Expanded partnership for private-label insulin glargine manufacturing and supply in US. Civica markets and distributes insulin under CalRx program at $11 per vial. Biocon manufactures insulin at Malaysia facility for US commercialization.
• Janssen Biotech Inc.coreStrategic or Co-development Partner · 1 January 2024Biosimilar commercialization agreement for unspecified biosimilar products. Deal part of Biocon's strategy to expand biosimilar portfolio globally.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Celltrion: South Korean biosimilars company with a comparable fully integrated biosimilars portfolio (Remsima, Truxima, Herzuma, etc.) targeting the same reference biologics in oncology and immunology. Closest direct competitor in scale and commercialization model.
• Samsung Bioepis: Joint venture between Samsung Biologics and Biogen developing biosimilars in oncology, immunology, and ophthalmology. Direct competitor in interchangeable biosimilar filings and US market share capture.
• Alvotech: Iceland-based biosimilar developer with interchangeable biosimilar programs in ophthalmology (aflibercept) and immunology. Competes head-to-head in US interchangeable biosimilar space.

Broad incumbents

• Sandoz (Novartis): Global biosimilars and generics leader with a broad biosimilars portfolio (Hyrimoz, Omnitrope, Erelzi) and full pharmaceutical infrastructure. Overlaps with Biocon across most biosimilar molecules but operates at much larger scale.
• Amgen: Originator of Prolia/Xgeva (denosumab), Stelara (ustekinumab), and many other reference biologics that Biocon biosimilars compete against. Also a partner via the Amgen settlement for EU denosumab launches.
• Viatris (Mylan): Former commercial partner from which Biocon acquired the global biosimilars business for $3.3B. Continues as a residual minority stakeholder and broader pharmaceutical peer in biosimilars/commercialization.

Emerging players

• mAbxience: Insud Pharma's biosimilars arm with oncology-focused biosimilars (rituximab, trastuzumab, bevacizumab) competing in EU and emerging markets. Comparable emerging-market commercial model and biosimilar pipeline scope.
• Fujifilm Kyowa Kirin Biologics (FKB): Former adalimumab biosimilar (Hulio) partner that transferred full global rights to Biocon in December 2025. Overlapping biosimilar development capabilities and pipeline.

Regional players

• Intas Pharmaceuticals: Indian biopharmaceutical company with biosimilars (Accofil, Neukine) and a global specialty injectables footprint. Comparable in Indian-origin manufacturing scale and emerging market commercialization.

Others

• Syngene International: Biocon Group's listed CRDMO arm providing contract biomanufacturing and research services. Sister company and ecosystem enabler, not a direct competitor but a key adjacent business within the Biocon Group.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biocon-biologics
• Xx.com/bioconlimited
• Facebookfacebook.com/bioconlimited

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocon Biologics